'We strong­ly dis­sent': Women biotech ex­ecs pen let­ter to col­leagues and politi­cians in Roe v. Wade af­ter­math ...

Up until recently, Alban de La Sablière was Sanofi’s chief dealmaker, reporting directly to CEO Paul Hudson without officially being a C-suite executive. That's now changed with de La Sabli ...

Ada­gio raised $750M+ for an an­ti­body against fu­ture vari­ants. It failed against Omi­cron ...

The next generation of Operation Warp Speed is coming soon, and this time it's going to take aim at rare diseases, Peter Marks, the director of the FDA's Center for ...

Merck and Kelun-Biotech revealed Phase 3 breast cancer data for the lead antibody-drug conjugate in their potentially $12 billion partnership. In a Phase 3 trial for locally recurrent or ...

The FDA is hoping its latest solution will stave off the continued shortage of cisplatin, a key drug used in treating several types of cancer. Beginning ...

In early August, Teva hit a bump in producing the popular ADHD drug Adderall, as the company faced a backorder of the drug in 20 mg and 30 mg ...

For­mer Spark ex­ec to lead a gene ther­a­py up­start of his own; Big Phar­ma mar­ket­ing vet named CEO of Swiss biotech ...

Un­der the gun with Aduhelm floun­der­ing, Bio­gen sells its stake in biosim­i­lars busi­ness for $2.3B ...

Senate Finance Committee Chair Ron Wyden (D-OR) is urging HHS to take a stronger stance on healthcare companies' cybersecurity practices as the healthcare system is still piecing together what ...

It’s big days for biology. The pandemic has seen a series of very public scientific breakthroughs: mRNA vaccine, Covid antibodies, CRISPR as therapy. The minds behind these advancements have ...

Mod­er­na preps for a pri­vate, more ex­pen­sive Covid-19 vac­cine mar­ket as Biden ad­min frets over un­in­ten­tion­al shift ...